Status:
COMPLETED
Transperineal Versus Transrectal Prostate Biopsy
Lead Sponsor:
Maastricht University Medical Center
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
Background: Prostate biopsies are essential to diagnose prostate cancer (PCa). Transrectal prostate biopsies (TR-PB) are commonly performed, however disadvantages include the requirement of antibiotic...
Eligibility Criteria
Inclusion
- men who underwent prostate biopsy between 2017-2018 (transrectal)
- men who underwent prostate biopsy between 2012-2022 (transperineal)
Exclusion
- positive urine culture before biopsy
- patients in the transrectal biopsy group who did not take the prescribed course of antibiotic prophylaxis
- incomplete medical dossier where the occurrence of a complication could not be assessed
Key Trial Info
Start Date :
April 15 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 18 2023
Estimated Enrollment :
923 Patients enrolled
Trial Details
Trial ID
NCT06027203
Start Date
April 15 2023
End Date
July 18 2023
Last Update
September 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maastricht University Medical Center
Maastricht, Netherlands, 6229HX